Apostolos Stathopoulos

MD, PhD: Founder & CEO
Apostolos Stathopoulos, MD, PhD: Founder & CEO
Head of Neurosurgical Service at Henry Dunant - Athens, Greece
Clinical Assistant Professor at the University of Southern California (USC)
PhD in Immunology from Wageningen University (The Netherlands) in 2012
ERC Belgium Brain Cancer company founder in 2008
Graduated as Neurosurgeon from University of Liege in 2006 (Belgium)
Neuro-Oncology fellowship certificate from USC in 2005
Received his M.D. from the Free University of Brussels - ULB (in Belgium) in 2000
For more information on A. Stathopoulos, visit Immunoneurosurgery.com

Bernard Questier

B.A, Vice-President
Mr. Questier brings more than 25 years of international experience in various management positions
Former Vice President, Europe and Asia Pacific for medical devices, and Worldwide Head of Molecular Business at Ventana Medical Systems, from 1996 untill late 2003
Before 1996, Bernard had several international management positions in the medical business of DuPont de Nemours
Bernard has a Bachelor’s degree in Chemistry from Hoger Technisch Instituut, Oostende (Belgium)

Bernard Alliaume

MD: Co-founder, Vice President, Chief Administrative Officer and Head of Human Resources
Anesthesiologist, involved in cardiac, thoracic, abdominal, and neuro-surgery at the Regional Hospital Center, Namur, Belgium
Co-founder of ERC Belgium Brain Cancer company with Apostolos Stathopoulos, in 2008
President of the Medical and Pharmaceutical Hospital Commission from 2004 to 2009
Received his Doctorate in Medical Science from Catholic University Louvain, Belgium, in 1987

Virgil Schijns

PhD: Chief Scientific Officer (CSO) & President of ERC-The Netherlands and QP for Manufacturing
Also, Registered Qualified Person (QO) for the GMP product Gliovac/ ERC 1671 and Registered Responsible Person (RP) of the Tumor Tissue bank (TTB-The Netherlands)

Guest Professor at Strathclyde University, Glasgow, Scotland, United Kingdom Professor of Immune intervention at Wageningen University, The Netherlands, Department Cell Biology & Immunology Special Professor in Immunology and Virology at North Carolina State University (NCSU), Previously, from 2008 to 2011, Virgil was Chief Technology Officer, Vice-president R&D at a Utrecht-University spin-off company, The Netherlands, a company that developed vaccines based on misfolded proteins From 2005 to 2007, principal Immunologist of Nobilon, a newly business unit of AKZONOBEL, dedicated to human vaccines Previously, more than 10 years Head of the Department of Vaccine Technology and Immunology at Intervet-AKZONOBEL Virgil has a Ph.D. from the Institute of Virology (Utrecht University) and the ITRI-TNO. Virgil published ca. 4 books, 12 Book Chapters / Monographs and more than 100 scientifc peer-reviewed articles.

Frédéric Desmedt

Vice-President, Director of investment and Acquisitions
Business manager in the finance field (broker since 2007), Frédéric Desmedt has a wide experience of 11 years as financial adviser (namely advice in investments and asset management).
Former top athlete (world champion of 1500 m Masters in 2007 and European champion of 800 m in athletics), he has started his professional carreer at the Royal Military Academy in the international sports elite.

Kostia Janssens

Director of company capitalization and VC network
Administrator of financial and real estate companies for several years. Commercial position during more than 15 years in the service to companies.

Mohamad Kassas

Director of Pharmaceutical affaires and development 
Pharmacist (Free University of Brussels - ULB) 
Specialisation Diploma in Pharmaceutical science ad Biological analaysis 
Specialisation Diploma in Clinical analaysis
Specialisation Diploma in Immuno-Hematologic transfusion